Healthcare provider profile · identity verified

Michael Hernandez, MD

Internal Medicine · JACKSONVILLE, FL · NPI 1609929405

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	191	89
Amlodipine Besylate	Amlodipine Besylate	174	90
Rosuvastatin Calcium	Rosuvastatin Calcium	141	68
Gabapentin	Gabapentin	139	72
Losartan Potassium	Losartan Potassium	130	63
Albuterol Sulfate Hfa	Albuterol Sulfate	111	60
Carvedilol	Carvedilol	108	51
Fluticasone Propionate	Fluticasone Propionate	104	58
Pantoprazole Sodium	Pantoprazole Sodium	92	55
Eliquis	Apixaban	91	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	90	42
Prednisone	Prednisone	85	59
Metformin Hcl Er	Metformin Hcl	82	33
Levothyroxine Sodium	Levothyroxine Sodium	79	36
Diclofenac Sodium	Diclofenac Sodium	78	53
Omeprazole	Omeprazole	78	45
Tamsulosin Hcl	Tamsulosin Hcl	78	43
Trazodone Hcl	Trazodone Hcl	71	32
Metoprolol Succinate	Metoprolol Succinate	70	39
Potassium Chloride	Potassium Chloride	70	37
Furosemide	Furosemide	68	48
Montelukast Sodium	Montelukast Sodium	63	24
Buspirone Hcl	Buspirone Hcl	56	29
Duloxetine Hcl	Duloxetine Hcl	56	36
Azithromycin	Azithromycin	53	41
Nifedipine Er	Nifedipine	53	22
Tizanidine Hcl	Tizanidine Hcl	50	30
Famotidine	Famotidine	49	29
Hydrochlorothiazide	Hydrochlorothiazide	47	27
Triamcinolone Acetonide	Triamcinolone Acetonide	47	34
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	44	17
Meloxicam	Meloxicam	41	25
Metformin Hcl	Metformin Hcl	41	21
Sertraline Hcl	Sertraline Hcl	40	22
Spironolactone	Spironolactone	38	22
Cefdinir	Cefdinir	34	22
Pioglitazone Hcl	Pioglitazone Hcl	32	17
Allopurinol	Allopurinol	31	16
Alendronate Sodium	Alendronate Sodium	30	17
Mirtazapine	Mirtazapine	28	18
Tramadol Hcl	Tramadol Hcl	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	14
Glipizide Er	Glipizide	26	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	25	16
Lisinopril	Lisinopril	24	14
Topiramate	Topiramate	24	11
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Entresto	Sacubitril/Valsartan	22	suppressed
Lactulose	Lactulose	22	14
Hydralazine Hcl	Hydralazine Hcl	21	17
Pregabalin	Pregabalin	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Sildenafil Citrate	Sildenafil Citrate	20	11
Cephalexin	Cephalexin	18	17
Aripiprazole	Aripiprazole	17	suppressed
Glipizide	Glipizide	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Ibuprofen	Ibuprofen	16	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	13
Levetiracetam	Levetiracetam	15	suppressed
Ondansetron Odt	Ondansetron	15	15
Ozempic	Semaglutide	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Levofloxacin	Levofloxacin	13	11
Bumetanide	Bumetanide	12	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error